AvPAK

Pharmaunternehmen2 erfasste Produkte

erfasste Produkte

22.105

Meldungen insgesamt

dokumentierte Rückrufe

63,2%

schwerwiegend insgesamt

Produkte

2 von 2 angezeigt

Produkt	Zugelassen	Meldungen ↓	Top-Signal	Rückrufe
isosorbide dinitrate —	1968	19.613	Vorübergehende Durchblutungsstörung des Gehirns	8
artificial tears —	—	2.492	Endokrine Ophthalmopathie	20

Rückrufhistorie · 26 dokumentiert

Datum	Klasse	Grund	Firma
25. März 2026	II	Lack of Assurance of Sterility	Preferred Pharmaceuticals, Inc.
3. März 2026	II	Lack of Assurance of Sterility	K.C. Pharmaceuticals, Inc
3. März 2026	II	Lack of Assurance of Sterility	K.C. Pharmaceuticals, Inc
23. Apr. 2025	II	cGMP deviations and lack of assurance of sterility.	BRS Analytical Services, LLC
13. Juni 2023	II	CGMP Deviations: good manufacturing deficiencies related to a lack of documentation of the fill line.	K.C. Pharmaceuticals, Inc
26. Apr. 2023	II	CGMP Deviations: Firm went out of business and could no longer continue stability studies.	Akorn, Inc.
30. Jan. 2023	I	Non-Sterility: FDA analysis found unopened products to have bacterial contamination.	Global Pharma Healthcare Private Limited
30. Jan. 2023	I	Non-Sterility: FDA analysis found unopened products to have bacterial contamination.	Global Pharma Healthcare Private Limited
30. Jan. 2023	II	CGMP Deviations: All other lots of eye drops are being recalled due to CGMP Deviations because they were manufactured in the same facility under the same conditions as the lots found to be contaminated.	Global Pharma Healthcare Private Limited
30. Jan. 2023	II	CGMP Deviations: All other lots of eye drops are being recalled due to CGMP Deviations because they were manufactured in the same facility under the same conditions as the lots found to be contaminated.	Global Pharma Healthcare Private Limited
13. Okt. 2022	II	CGMP Deviations:	Akorn, Inc.
13. Okt. 2022	II	CGMP Deviations:	Akorn, Inc.
2. Aug. 2021	II	Non-Sterility - OOS sterility testing observed during 12-month controlled room temperature stability testing. The microbiological investigation identified the organism as a member of the Bacillus cereus group.	Akorn, Inc.
2. Nov. 2018	II	Cross Contamination with Other Products	Sandoz Inc
2. Nov. 2018	II	Cross Contamination with Other Products	Sandoz Inc
2. Nov. 2018	II	Cross Contamination with Other Products	Sandoz Inc
2. Nov. 2018	II	Cross Contamination with Other Products	Sandoz Inc
14. Nov. 2014	II	Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.	Attix Pharmaceuticals
2. Juli 2013	II	Labeling:Label Mixup; ISOSORBIDE DINITRATE ER Tablet, 40 mg may be potentially mislabeled as CILOSTAZOL, Tablet, 50 mg, NDC 60505252101, Pedigree: AD21811_7, EXP: 5/1/2014.	Aidapak Services, LLC
2. Juli 2013	II	Labeling: Label Mixup: ISOSORBIDE DINITRATE, Tablet, 5 mg may have potentially been mislabeled as one of the following drugs: CILOSTAZOL, Tablet, 100 mg, NDC 00054004421, Pedigree: W003470, EXP: 6/20/2014; PERPHENAZINE, Tablet, 8 mg, NDC 00630506221, Pedigree: AD54605_1, EXP: 4/30/2014.	Aidapak Services, LLC
2. Juli 2013	II	Labeling: Label Mixup: ISOSORBIDE DINITRATE, Tablet, 10 mg may have potentially been mislabeled as one of the following drugs: SODIUM CHLORIDE, Tablet, 1 mg, NDC 00223176001, Pedigree: AD22845_10, EXP: 5/2/2014; CALCITRIOL, Capsule, 0.5 mcg, NDC 63304024001, Pedigree: AD32757_10, EXP: 5/14/2014.	Aidapak Services, LLC
25. Mai 2012	II	Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.	Franck's Lab Inc., d.b.a. Franck's Compounding Lab
25. Mai 2012	II	Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.	Franck's Lab Inc., d.b.a. Franck's Compounding Lab
25. Mai 2012	II	Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.	Franck's Lab Inc., d.b.a. Franck's Compounding Lab
25. Mai 2012	II	Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.	Franck's Lab Inc., d.b.a. Franck's Compounding Lab
25. Mai 2012	II	Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.	Franck's Lab Inc., d.b.a. Franck's Compounding Lab

Klasse I = begründete Wahrscheinlichkeit schwerwiegender Schäden · Klasse II = vorübergehend oder reversibel · Klasse III = Schaden unwahrscheinlich.

Registrierungsstatus

Einige Produkte von AvPAK sind nicht für die Anwendung am Menschen FDA-registriert. Für nicht registrierte Substanzen (Peptide, SARMs ohne Humanzulassung) existiert kein legitimer Anbieter für die Anwendung am Menschen. Das Fehlen eines Bezugswegs ist die Sicherheitsinformation.